494861-75-5Relevant academic research and scientific papers
Discovery of novel orally active ureido NPY Y5 receptor antagonists
Li, Guoqing,Stamford, Andrew W.,Huang, Ying,Cheng, Kuo-Chi,Cook, John,Farley, Constance,Gao, Jun,Ghibaudi, Lorraine,Greenlee, William J.,Guzzi, Mario,van Heek, Margaret,Hwa, Joyce J.,Kelly, Joe,Mullins, Deborra,Parker, Eric M.,Wainhaus, Sam,Zhang, Xiaoping
, p. 1146 - 1150 (2008/09/18)
We have derived a novel series of neuropeptide Y (NPY) Y5 receptor antagonists from the biphenylurea 3. Cyclohexylurea 21c, a member of the series, is a potent NPY Y5 receptor antagonist that exhibits excellent pharmacokinetic parameters in rats and dogs. On chronic oral administration to diet-induced obese rats, 21c displayed an anti-obesity profile, causing a modest reduction in food intake, a significant decrease in body weight gain, a decrease in adipose mass, and an increase in lean tissue mass.
